Background and Objective: Atrial fibrillation is a common complication after lung resection. We sought to determine the relationship between low-dose landiolol only intraoperatively administration and the incidence of atrial fibrillation development in patients who did not have atrial fibrillation before undergoing lung resection. Methods: Forty-five patients undergoing lung resection (lobectomy or bilobectomy), as indicated for lung cancer at Nippon Medical Hospital, between August 2012 and September 2013. Two patients were excluded from the final analysis. Patients were given either intravenous landiolol (n = 22) or placebo (n = 21) during lobectomy or bilobectomy only intraoperatively. This is prospective, randomized, placebo-controlled study. Main Outcome Measures: The primary end point was the incidence of sustained atrial fibrillation (≥30 min). Results: Postoperative atrial fibrillation occurred in 1 (4.5%) of the 22 patients in the landiolol group and 6 (28.6%) of the 21 patients in the placebo group. No serious adverse effects such as bradycardia and hypotention secondary to landiolol were observed. Conclusion: Low-dose landiolol infusion intraoperatively reduced the incidence of clinically significant atrial fibrillation in patients undergoing pulmonary lobectomy.
Atrial Fibrillation (AF) is one of the most common complications after thoracic surgery. In addition to reducing quality of life and causing palpitations and cardiac hypofunction, AF also increases the risk of cardiogenic embolus. Therefore, it is necessary to prevent the development of AF in patients undergoing thoracic surgery.
AF often occurs after cardiac surgery. For this reason, various studies have investigated means of inhibiting AF after cardiac surgery. One such study used landiolol. This study, the JL-NIGHT study, demonstrated that intraoperative administration of landiolol hydrochloride reduces the incidence of AF after open-heart surgery [
The study protocol was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN000007561). Ethical approval for this study (Protocol number 223009) was provided by the Institutional Review Board of Nippon Medical School Hospital, Tokyo, Japan, (Chairperson: Hospital director Sakamoto) on August 8, 2011. We obtained written informed consent from all patients on the day before surgery. This study included 45 patients undergoing lung resection at Nippon Medical School Hospital between August 2012 and September 2013. The indication for lung resection in all subjects was lung cancer, which required treatment with lobectomy or bilobectomy. The patients were randomized to receive landiolol (2.5 μg∙kg−1∙min−1) (Ono Pharmaceutical Co., Osaka, Japan), or an identical amount of saline as a placebo. Both landiolol and the placebo were administered, intravenously during anesthesia. All patients had an American Society of Anesthesiologists (ASA) physical status of I/II. The exclusion criteria were acute myocardial infarction within 3 days prior to surgery, a history of supraventricular arrhythmia requiring treatment, sinus node disease, presence of a permanent pacemaker, severe heart failure (New York Heart Association III/IV or ejection fraction <35%), atrioventricular block (AV block ≥ second degree), contraindications to β-blocker therapy, secondary AF with a known primary cause (e.g., electrolyte imbalance, Wolff-Parkinson-White syndrome or hyperthyroidism), hypotension (<90/60 mmHg), and the perioperative use of an anti-arrhythmic agent other than digitalis.
At enrolment in the study, the patients were randomized using the sealed envelope method to receive either the placebo or the study drug. Patients were continuously monitored from immediately after surgery for up to 72 hours thereafter. Landiolol or saline was administered from the start of anesthesia as a continuous infusion at an initial rate of 2.5 μg∙kg−1・min−1, which was titrated to a maximum rate of 20 μg∙kg−1∙min−1 (reassessed every 10 min) based on the hemodynamic or electrocardiographic response. The maintenance infusion of landiolol was titrated upward to maintain the ventricular rate at <90 beats/min. If hypotension (systolic blood pressure < 90 beats/min) or bradycardia (heart rate < 50 beats/min) occurred, the dose was reduced or infusion of the drug was discontinued until symptoms resolved.
The Holter electrocardiogram (ECG) was recorded on a secure digital (SD) card-type recorder (Fukuda Denshi 600; Fukuda Denshi Co., Tokyo, Japan). Postoperative recording was initiated after the surgery and continued for 72 hours.
The occurrence of episodes of AF lasting more than 30 minutes was considered as the study endpoint. More specifically, the primary endpoint was the frequency of AF occurrence from the end of the surgery to 72 hours thereafter.
Age, height, and weight were recorded for each patient. Information was also collected on preoperative pulmonary status, which was expressed as the percentage of the predicted value of forced vital capacity.
Continuous variables are expressed as mean ± standard deviation (SD). Clinical characteristics of the two groups were compared using the independent t-test for continuous variables and the chi-square test for categorical variables. Adverse events were analyzed by the chi-square test, as appropriate. In all analyses, P < 0.05 was considered statistically significant.
One patient was excluded because the surgery type was changed intraoperatively, and another was excluded because of undergoing reoperation; hence, 43 patients completed the study. There were no statistically significant differences between the two groups in terms of sex, age, height, weight, and other preoperative data or the measured lung function parameters (
The numbers of patients with arrhythmias are provided (
With respect to side effects, hypotension, bradycardiaand other serious eventswere not observed in either group.
| Landiolol | Placebo | P | |
|---|---|---|---|
| No. of patients | 22 | 21 | |
| Perioperative data | |||
| Gender (male) | 9 | 12 | 0.12 |
| Age (years) | 70.9 ± 7.54 | 69.1 ± 7.10 | 0.34 |
| Height (cm) | 156 ± 8.3 | 158 ± 9.8 | 0.29 |
| Weight (kg) | 51.9 ± 7.3 | 55 ± 10.4 | 0.21 |
| FEV1% | 70.6 ± 4.96 | 73.3 ± 9.30 | 0.30 |
| VC | 119 ± 25.5 | 110 ± 18.9 | 0.24 |
| Perioperative data | |||
| Bilobectomy | 2 | 0 | 0.16 |
| Anesthesia time (min) | 212 ± 86.8 | 228 ± 78.5 | 0.80 |
| Operation time (min) | 323 ± 110 | 331 ± 101 | 0.52 |
FEV1%: forced expiratory volume in 1 s; VC: vital capacity; Values are mean ± SD numbers.
| Landiolol | Placebo | P | |
|---|---|---|---|
| No. of patients | 22 | 21 | |
| Partial block | 6 | 2 | 0.10 |
| Negative T wave | 0 | 1 | 0.32 |
| Sinus arrhythmia | 8 | 5 | 0.27 |
| Atrial fibrillation | 1 | 6 | *0.03 |
*P < 0.05.
| Landiolol | Placebo | P | |
|---|---|---|---|
| Preoperative | 70.2 ± 14.6 | 73.3 ± 12.2 | 0.23 |
| Postoperative-24 hour | 78.9 ± 11.3 | 76.6 ± 9.9 | 0.52 |
| 24 - 48 hour | 80.0 ± 12.6 | 82.8 ± 10.7 | 0.48 |
| 48 - 72 hour | 82.6 ± 11.3 | 83.3 ± 7.7 | 0.87 |
This study has two main findings. First, landiolol decreases the incidence of AF for up to 72 hours after surgery. In this study, AF onset occurred an average of 2.7 days after surgery. This result is, therefore, similar to the findings of previous studies, which have stated that AF is prone to occur from 2 or 3 days after surgery [
The present study demonstrated that landiolol decreases the incidence of intraoperative AF with only a small dose. Studies of a similar-blocker, metoprolol, have also shown a significant reduction in the incidence of AF [
The mechanism of AF onset after thoracic surgery remains unclear, although the origin of AF and its association with the pulmonary vein have both been demonstrated. In AF, frequent local excitation (premature atrial contraction) is the trigger for the initial formation and onset of reentry arrhythmia. Haissaguerre et al. reported that the aberrant excitation that triggers AF mostly originates in the atrial muscle in the pulmonary veins [
Although it is not entirely clear why handling of the pulmonary vein triggers AF, our findings show a strong correlation between AF and thoracic surgery. Indeed, AF occurred in 17% of our patients, including 28% of those in the control group and 5% of those in the landiolol group (P = 0.03). These findings indicate that the incidence of AF was significantly inhibited in the group of patients who received landiolol.
Our findings demonstrate that administration of landiolol during surgery decreased the incidence of AF following lung resection. Although-blockers, such as landiolol, are known to reduce perioperative increases in sym- pathetic nervous system (SNS) activity and reduce AF onset, the underlying mechanisms of these changes remain unclear. Further research is needed to determine the optimal dose of landiolol required to reduce AF onset.
Our study has the following limitations. First, the incidence of AF was greater than those in many previous reports. This was attributed to the high percentage of elderly patients in the present study, and in fact, the mean age of the seven patients who developed AF was 82 years. It is known that aging causes degenerative changes in atrial anatomy that are accompanied by a shorter atrial effective refractory period, longer sinoatrial and atrioventricular nodal conduction times, atrial stiffening, and splitting of the atrial excitation waveform by the pectinate trabeculae [
In conclusion, perioperative landiolol administration was found to be an effective means of reducing the incidence of atrial fibrillation after pulmonary lobectomy.
Kaori Yagi,Jitsuo Usuda,Atsuhiro Sakamoto, (2016) Perioperative Landiolol Infusion Reduces the Incidence of Atrial Fibrillation after Pulmonary Lobectomy: Postoperative Randomized Controlled Study. Open Journal of Anesthesiology,06,119-123. doi: 10.4236/ojanes.2016.68020